IDH2 and glioblastoma: Glioblastoma, IDH-wildtype is molecularly characterized by TERT promoter (TERTp) mutation, EGFR amplification, or chromosome 7 gain and 10 loss (7 +/10−), in addition to characteristic pathological findings such as necrosis and microvascular proliferation.